Published in Drug Week, July 28th, 2006
The move is one of a series of strategic managerial appointments made by the company in preparation for clinical trials with its lead product, ACE393, the world's first commercial vaccine for travelers' diarrhea (TD) caused by Campylobacter infection.
Schrotz-King is 41-years-old and has worked at Ace BioSciences for the last 5 years, most recently as VP of Drug Discovery. In this capacity she has delivered on key company milestones including those to progress ACE393 from lead candidate selection through to the clinic in just 20 months. She has also helped...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.